References

  1. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a de?ned urban population. J Intern Med. 1992;232(2): 155-160. PubMed| Google Scholar

  2. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT study. Arch Intern Med. 1991; 151(5): 933-938. PubMed| Google Scholar

  3. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998; 158 (6):585-59. PubMed| Google Scholar

  4. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999; 353(9159):1167-1173. PubMed| Google Scholar

  5. Mahé I, Caulin C, Bergmann JF: Age, an independent risk factor for thrombosis. epidemiologic data. Presse Med. 2005; 34(12):878-886. PubMed| Google Scholar

  6. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000; 83(5): 657-660. PubMed| Google Scholar

  7. Mahé I, Caulin C, Bergmann JE. What explains the increased rate of thromboses among the elderly: Pathophysiological data. Presse Med. 2005; 34(12): 887-895. PubMed| Google Scholar

  8. Pottier P, Hardouin JB, Lejeune S, Jolliet P, Gillet B, Planchon B. Immobilization and the risk of venous thromboembolism. A meta-analysis on epidemiological studies. Thromb Res. 2009; 124(4) :468-476. PubMed| Google Scholar

  9. Isma N, Svensson PJ, Gottsater A, Lindblad B. Prospective analysis of risk factors and distribution of venous thromboembolism in the population-based Malmo Thrombophilia Study (MATS). Thromb Res. 2009; 124(6): 663-666. PubMed| Google Scholar

  10. Ouldzein H, Nourredine A, Cherradi R, Rahal N, Mechmeche R, Haouala. H. Management of pulmonary embolism in a cardiology department. Ann Cardiol Angeiol (paris). 2008; 57(1):52-57. PubMed| Google Scholar

  11. Healy B, Levin E, Perrin K, Weatherall M, Beasley R. Prolonged work- and computer-related seated immobility and risk of venous thromboembolism. J R Soc Med. 2010; 103(11): 447-454. PubMed| Google Scholar

  12. Fletcher HM, Wharfe G, Williams NP, Pedican M, Brooks A, Scott P, Gordon-Strachan G. Venous thromboembolism in Jamaican women: experience in a university hospital in Kingston. West Indian Med J. 2009; 58(3) :243-249. PubMed| Google Scholar

  13. Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997; 277 (8): 642-645. PubMed| Google Scholar

  14. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002; 162(10): 1182-1189. PubMed| Google Scholar

  15. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ 3rd. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population- based study. Arch Intern Med. 2002 ; 162 (11):1245-1248. PubMed| Google Scholar

  16. Agnelli G. Prevention of venous thromboembolism in surgical patients. Circulation. 2004; 110 (24 Suppl 1): IV4-IV12. PubMed| Google Scholar

  17. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl):338S-400S. PubMed| Google Scholar

  18. Bulger CM, Jacobs C, Patel NH. Epidemiology of acute deep vein thrombosis. Tech Vasc Interv Radiol. 2004; 7(2):50-54. PubMed| Google Scholar

  19. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339: b2921. PubMed| Google Scholar

  20. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009; 339: b2890. PubMed| Google Scholar

  21. Hannaford PC. Epidemiology of the contraceptive pill and venous thromboembolism. Thromb Res. 2011;127(suppl3):S30-S34. PubMed| Google Scholar

  22. van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous thromboembolism: where are we now? J Thromb Haemost. 2011; 9(2): 257?266. Google Scholar

  23. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001; 323 (7305):131-134. PubMed| Google Scholar

  24. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011; 342:d2139. PubMed| Google Scholar

  25. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011; 342:d2151. PubMed| Google Scholar

  26. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost. 1997; 78(1) :315-326. PubMed| Google Scholar

  27. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma BN, Büller HR, Prins MH, Tans G. Low- dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet .1999; 354(9195):2036-2040. PubMed| Google Scholar

  28. Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, Tans G, Rosing J, Prins MH, Büller HR. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost. 2000; 84(1):4-8. PubMed| Google Scholar

  29. Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, Bouma BN, Büller HR, Rosing J. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000; 84(1):15-21. PubMed| Google Scholar

  30. Alhenc-Gelas M, Plu-Bureau G, Guillonneau S, Kirzin JM, Aiach M, Ochat N, Scarabin PY. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost. 2004; 2(9):1594-1600. PubMed| Google Scholar

  31. van Vliet HA, Bertina RM, Dahm AE, Rosendaal FR, Rosing J, Sandset PM, Helmerhorst FM. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost.2008;6(2):346-351. PubMed| Google Scholar

  32. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?. Acta Obstet Gynecol Scand. 2002; 81(6): 482-490. PubMed| Google Scholar

  33. Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH, Kuhl H. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception. 2003; 67(1):25-32. PubMed| Google Scholar

  34. van Vliet HA, Frolich M, Christella M, Thomassen LG, Doggen CJ, Rosendaal FR, Rosing J, Helmerhorst FM. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod. 2005; 20(2):563-568. PubMed| Google Scholar

  35. Rad M, Kluft C, Ménard J, Burggraaf J, de Kam ML, Meijer P, Sivin I, Sitruk-Ware RL. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. Am J Obstet Gynecol .2006; 195(1): 72-77. PubMed| Google Scholar

  36. van Vliet HA, Rosendaal FR, Rosing J, Helmerhorst FM . Sex hormone-binding globulin: an adequate surrogate marker for venous thromboembolism in women using new hormonal contraceptives. Contraception. 2009; 79(4): 328-329. PubMed| Google Scholar

  37. Meissner MH, Chandler WL, Elliott JS. Venous thromboembolism in trauma: A local manifestation of systemic hypercoagulability?. Journal of Trauma- Injury, Infection and Critical Care. 2003; 54(2):224-231. PubMed| Google Scholar

  38. Benhamou Y, Marie I, David N, Gbaguidi X, Cailleux N, Peillon C, Plissonnier D, Lévesque H. Upper limb deep venous thrombosis. Rev Med Interne. 2011;32(9) :567-574. PubMed| Google Scholar

  39. Anderson FA Jr, Wheeler HB. Physician practices in the management of venous thromboembolism: a community-wide survey. J Vasc Surg. 1992; 16(5):707-714. PubMed| Google Scholar

  40. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet .1999; 354(9176): 407-413. PubMed| Google Scholar

  41. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996; 125(1):1-7. PubMed| Google Scholar

  42. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med .1997; 336(6):393-398. PubMed| Google Scholar

  43. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000; 160(6):769-774. PubMed| Google Scholar